English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, October 28, 2020
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
エーザイ、第13回アルツハイマー病臨床試験会議(CTAD)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform
Tuesday, October 27, 2020
Global Coalition for Adaptive Research・アムジェン・エーザイ、COVID-19グローバル試験に最初の患者様が登録されたことを発表
Monday, October 26, 2020
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
エーザイ、Cogstate社のデジタル認知機能評価技術の開発権と商業化権に関する契約をグローバルに拡大することに合意
Thursday, October 22, 2020
エーザイ、アデュカヌマブの欧州医薬品庁への販売承認申請の提出について
Friday, October 16, 2020
エーザイ、抗てんかん剤「フィコンパ(R)」について中国で部分てんかんの単剤療法および小児適応の追加申請が受理
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Thursday, October 8, 2020
The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575